Human metabolism trial

Titlesort descending Average Rating
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
Association between serum 25(OH)D and death from prostate cancer. 70.00%
Bioavailability of sorafenib tablets administered as a liquid suspension. 30.00%
Biophotonics in the infrared spectral range reveal acupuncture meridian structure of the body. 95.00%
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non 50.00%
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. 60.00%
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy 90.00%
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy 50.00%
Clinical studies of Ukrain in healthy volunteers (phase 1). 60.00%
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... 50.00%
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocy.. 80.00%
Evaluation of Ukrain as an immunostimulant in patients with various carcinomas. 63.33%
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and re 70.00%
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, 50.00%
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid 55.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
New biochemical mechanisms of the anticancer effect of Ukrain in the treatment of cancer of the urinary bladder 60.00%
p53 as a specific prognostic factor in triple-negative breast cancer. 75.00%
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity........... 90.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. 60.00%